NCT01354691 - Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

March 31, 2013

Conditions

Alzheimer's DiseaseDementiaMemory LossCognitive Impairment

Interventions

DRUG

ladostigil hemitartrate

Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.

Trial Locations (19)

1130

Privatordination, Lainzerstrasse 20, Wein

3580

Privatordination Horn, HamerlingstraBe 15, Horn

4020

Allgemeines Krankenhaus der Stadt Linz, KrankenhausstraBe 9, Linz

8036

Medizinische Univeritat Graz, Universitatsklinik fur Neurologie, Auenbruggerplatz 22, Graz

10000

Clinical Hospital Center Zagreb, Kispaticeva 12, Zagreb

Clinical Hospital Dubrava, Avenija Gojka Suska 6, Zagreb

Polyclinic Neuron, Salata 12, Zagreb

10090

Psychiatric Hospital Vrapce, Bolnicka cesta 32, Zagreb

11000

Clinical Centre of Serbia, Dr. Subotica 6, Belgrade

Military Medical Academy, Crnotravska 17, Belgrade

17190

Institud d' Assistencia Sanitaria de Girona, Edifici La Republica - C/Dr. Castany, s/n, Salt

19055

Klinische Forschung Schwerin GmbH, FriedrichstraBe 1, Schwerin

20253

Klinische Forschung Hamburg GmbH, Hoheluftaussee 18, Hamburg

26655

Studienzentrum Nordwest, Lange StraBe 23-25, Westerstede

48993

CAE Oroitu Centro Atencion Especializada C/Jata, 9, Algorta

49210

General Hospital Zabok, Bracak 8, Zabok

52100

General Hospital Pula, Negrijeva 6, Pula

08004

Centro Geroinnova Barcelona, Calle Mandoni n 17, Barcelona

08014

Fundacio ACE, Institut Catala de Neurosciencies Aplicadas, C/Margues de Sentmenat 35-37, Barcelona